Cognito Therapeutics

Cognito Therapeutics is a clinical-stage neurotechnology company in Cambridge, Massachusetts, founded in 2016 out of MIT research by Ed Boyden and Li-Huei Tsai into the link between gamma-frequency neural oscillations and Alzheimer's disease progression. Its lead investigational product, Spectris, is a non-invasive at-home neuromodulation device that delivers synchronized 40Hz light and sound stimulation through a headset and glasses for one hour daily, evoking gamma activity to slow cognitive and functional decline in mild-to-moderate Alzheimer's disease. Spectris AD received FDA Breakthrough Device Designation in 2021, and the company closed an oversubscribed $105M Series C in March 2026 led by Morningside Ventures. Cognito Therapeutics is a medical device and therapeutics company: it publishes a corporate and clinical-information website and no public developer program, API, SDK, or machine-readable contract of any kind.

Cognito Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Health Care, Medical Devices, Neurotechnology, and Neuroscience.

🌐 Visit website 📡 Source on GitHub

9.6/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-05 · rubric v0.9.1

0 APIs

CompanyHealth CareMedical DevicesNeurotechnologyNeuroscienceAlzheimers DiseaseClinical TrialsDigital TherapeuticsBiotechnology

Kin Score

Kin Score How this is scored →
scored 2026-08-05 · rubric v0.9.1

Composite quality — 9.6/100 · minimal

Contract Quality 0.0 / 25

Developer Ergonomics 0.0 / 20

Commercial Clarity 2.1 / 20

Operational Transparency 0.7 / 13

Governance 0.0 / 12

Discoverability 6.9 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 10

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

A2A Agent Card 0 / 8

Dry-Run / Simulate Mode 0 / 4

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/cognito-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Agent Surfaces 1

MCP servers, agent skills, and machine-readable catalogs

LLMsTxt

LLMsTxt

Build 2

SDKs, sample code, and the tooling you integrate with

ClinicalStudies

ClinicalStudies

GitHubOrganization

GitHubOrganization

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Operate 2

Status, limits, changes, and where to get help

PressReleases

PressReleases

Contact

Contact

Commercial 1

Pricing, plans, and the legal terms of use

PrivacyPolicy

PrivacyPolicy

Company 3

The organization behind the API

Website

Website

About

About

Careers

Careers

Other 4

Properties that don't map to a standard resource type

Science

Resources

Publications

SecondaryMarket

Source (apis.yml)

aid: cognito-therapeutics
name: Cognito Therapeutics
description: 'Cognito Therapeutics is a clinical-stage neurotechnology company in Cambridge, Massachusetts, founded in 2016
  out of MIT research by Ed Boyden and Li-Huei Tsai into the link between gamma-frequency neural oscillations and Alzheimer''s
  disease progression. Its lead investigational product, Spectris, is a non-invasive at-home neuromodulation device that delivers
  synchronized 40Hz light and sound stimulation through a headset and glasses for one hour daily, evoking gamma activity to
  slow cognitive and functional decline in mild-to-moderate Alzheimer''s disease. Spectris AD received FDA Breakthrough Device
  Designation in 2021, and the company closed an oversubscribed $105M Series C in March 2026 led by Morningside Ventures.
  Cognito Therapeutics is a medical device and therapeutics company: it publishes a corporate and clinical-information website
  and no public developer program, API, SDK, or machine-readable contract of any kind.'
url: https://raw.githubusercontent.com/api-evangelist/cognito-therapeutics/refs/heads/main/apis.yml
image: https://cdn.prod.website-files.com/656e26ef10850ea6428fe577/65aa38ce4ab404d2ce4a2358_Opengraph-Cognito_(2).png
x-type: company
x-source: harvest:secondary-market
x-tier: profiled
x-tier-reason: enrichment-pass-no-api-surface
specificationVersion: '0.20'
created: '2026-08-02'
modified: '2026-08-02'
tags:
- Company
- Health Care
- Medical Devices
- Neurotechnology
- Neuroscience
- Alzheimers Disease
- Clinical Trials
- Digital Therapeutics
- Biotechnology
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Website
  url: https://www.cognitotx.com/
- type: About
  url: https://www.cognitotx.com/about
- type: Science
  url: https://www.cognitotx.com/science
- type: ClinicalStudies
  url: https://www.cognitotx.com/clinical-studies
- type: Resources
  url: https://www.cognitotx.com/resources
- type: PressReleases
  url: https://www.cognitotx.com/resources?category=Press+Releases
- type: Publications
  url: https://www.cognitotx.com/resources?category=Publications
- type: Careers
  url: https://www.cognitotx.com/careers
- type: Contact
  url: https://www.cognitotx.com/contact-us
- type: PrivacyPolicy
  url: https://www.cognitotx.com/privacy-policy
- type: GitHubOrganization
  url: https://github.com/Cognitotx
- type: SecondaryMarket
  url: https://forgeglobal.com/cognito-therapeutics_stock/
- type: DomainSecurity
  url: security/cognito-therapeutics-domain-security.yml
- type: LLMsTxt
  url: llms/cognito-therapeutics-llms.txt
x-enrichment:
  date: '2026-08-02'
  status: minimal
  artifacts_added: 3
  pass: local-v1